Block Listing Six Monthly Return

RNS Number : 0142E

Alliance Pharma PLC

02 July 2021

 

For immediate release

2 July 2021

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Block Listing Six Monthly Return

Name of applicant:		ALLIANCE PHARMA PLC
Names of schemes:		a)  The Alliance Pharma plc Approved Share Option Plan 2005 b)  The Alliance Pharma plc Share Option Plan 2006 c)  The Alliance Pharma plc Company Share Option Plan 2015
Period of return:	From:	28 December 2020	To:	28 June 2021
Number of securities originally admitted at date of admission:		25,000,000 ordinary shares of 1p each 28 June 2017
Balance of unallotted securities under schemes from previous return:		a)  293,372 b)  5,266,622 c)  13,265,746
Plus:   The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for):		a)  Nil b)  Nil c)  Nil
Less:   Number of securities issued/allotted under schemes during period:		a)  258,052 b) 317,909 c)  1,816,189
Equals:   Balance under schemes not yet issued/allotted at end of period:		d)  35,320 e)  4,948,713 f)  11,449,557

Name of contact:	Chris Chrysanthou, Company Secretary
Telephone number of contact:	Tel. [phone]

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
Numis Securities Limited	+ 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Oliver Steele
Corporate Broking: James Black

Investec Bank plc	+ 44 (0) 20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

END

 

 

BLRUUUKRABUBRRR